Summary
0.84 -0.03(-3.28%)06/26/2024
Adaptimmune Therapeutics Plc (ADAP)
Adaptimmune Therapeutics Plc (ADAP)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.28 | -1.47 | -14.98 | -39.78 | 48.39 | -5.64 | -78.21 | -94.58 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.84 | |
| Open | 0.87 | |
| High | 0.87 | |
| Low | 0.83 | |
| Volume | 1,357,018 | |
| Change | -0.03 | |
| Change % | -3.28 | |
| Avg Volume (20 Days) | 1,337,073 | |
| Volume/Avg Volume (20 Days) Ratio | 1.01 | |
| 52 Week Range | 0.42 - 2.05 | |
| Price vs 52 Week High | -59.15% | |
| Price vs 52 Week Low | 99.38% | |
| Range | -2.66 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 221 | |
| EBIDTA | -128,198,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.1100 | |
| WallStreet Target Price | 3.50 | |
| Book Value | 0.1740 | |
| Earnings Per Share | -0.5400 | |
| EPS Estimate Current Quarter | -0.1000 | |
| EPS Estimate Next Quarter | -0.1400 | |
| EPS Estimate Current Year | -0.2800 | |
| EPS Estimate Next Year | -0.4200 | |
| Diluted EPS (TTM) | -0.5400 | |
| Revenues | ||
| Profit Marging | -1.8890 | |
| Operating Marging (TTM) | -215.8268 | |
| Return on asset (TTM) | -0.2822 | |
| Return on equity (TTM) | -1.8761 | |
| Revenue TTM | 60,281,000 | |
| Revenue per share TTM | 0.3000 | |
| Quarterly Revenue Growth (YOY) | -0.9790 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -100,578,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.5026 | |
| Revenue Enterprise Value | 2.8989 | |
| EBITDA Enterprise Value | -1.3631 | |
| Shares | ||
| Shares Outstanding | 255,562,000 | |
| Shares Float | 987,097,907 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.39 | |
| Institutions (%) | 67.17 | |
06/17 14:05 EST - benzinga.com
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
By Michael Kim
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
By Michael Kim
06/03 12:00 EST - newsfilecorp.com
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, is presenting data from its pivotal IGNYTE-ESO trial of lete-cel (letetresgene autoleucel), an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual meeting. Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center will present "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" in an oral session at 11:30 a.m.
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, is presenting data from its pivotal IGNYTE-ESO trial of lete-cel (letetresgene autoleucel), an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual meeting. Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center will present "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" in an oral session at 11:30 a.m.
05/30 16:01 EST - globenewswire.com
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
05/30 16:01 EST - newsfilecorp.com
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
05/15 10:07 EST - seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis Williams - Head of Late Stage Development Cintia Piccina - Chief Commercial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright Peter Lawson - Barclays Operator Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis Williams - Head of Late Stage Development Cintia Piccina - Chief Commercial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright Peter Lawson - Barclays Operator Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.
05/15 07:30 EST - newsfilecorp.com
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCO Cash runway into late 2025 Conference call today at 8 a.m. EDT webcast link HERE Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the first quarter ended March 31, 2024.
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCO Cash runway into late 2025 Conference call today at 8 a.m. EDT webcast link HERE Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the first quarter ended March 31, 2024.
05/15 07:00 EST - newsfilecorp.com
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026.
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026.
05/01 12:00 EST - newsfilecorp.com
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
04/26 11:00 EST - seekingalpha.com
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon.
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon.
04/15 15:16 EST - zacks.com
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
04/12 08:00 EST - newsfilecorp.com
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entered in 2021, has been terminated. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "We've had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform.
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entered in 2021, has been terminated. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "We've had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform.
03/27 19:30 EST - newsfilecorp.com
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and translational results from afami-cel's SPEARHEAD-1 trial (NCT04044768).
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and translational results from afami-cel's SPEARHEAD-1 trial (NCT04044768).
03/06 09:29 EST - seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Jo Brewer - Chief Scientific Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities Jonathan Chang - Leerink Partners Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's Fourth Quarter and Year-End Conference Call and Business Update. I will now turn the call over to Juli Miller.
Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Jo Brewer - Chief Scientific Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities Jonathan Chang - Leerink Partners Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's Fourth Quarter and Year-End Conference Call and Business Update. I will now turn the call over to Juli Miller.
03/06 07:00 EST - newsfilecorp.com
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams preparing for product delivery Lete-cel program transitioned back to Adaptimmune and the Company is planning for US commercial launch in 2026 Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million Cash runway into early 2026; with greater than $300 million including current cash on hand, future expected income from partners and projected other non-dilutive capital sources Webcast to be held today, March 6, 2024, at 8:00 a.m. EST. (1:00 p.m.
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams preparing for product delivery Lete-cel program transitioned back to Adaptimmune and the Company is planning for US commercial launch in 2026 Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million Cash runway into early 2026; with greater than $300 million including current cash on hand, future expected income from partners and projected other non-dilutive capital sources Webcast to be held today, March 6, 2024, at 8:00 a.m. EST. (1:00 p.m.
02/27 08:00 EST - newsfilecorp.com
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023.
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023.
02/21 16:00 EST - newsfilecorp.com
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
01/31 16:44 EST - newsfilecorp.com
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024.
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024.
01/16 12:47 EST - zacks.com
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
01/04 07:37 EST - newsfilecorp.com
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024 Company preparing for US launch of afami-cel in 2H 2024 upon expected approval Pivotal trial for lete-cel met its primary endpoint for efficacy; full data set in Q3 2024 Company working toward approval of lete-cel; planning for US commercial launch in 2026 Company funded into early 2026 with > $300 million including existing balance sheet, projected payments from partners, and other non-dilutive capital sources Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 4, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the Company's plans for its emerging sarcoma franchise including projections for peak US sales of up to $400 million. The Company will present plans for the franchise at the JP Morgan Healthcare Conference on January 11th from 8:15 to 8:55 a.m.
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024 Company preparing for US launch of afami-cel in 2H 2024 upon expected approval Pivotal trial for lete-cel met its primary endpoint for efficacy; full data set in Q3 2024 Company working toward approval of lete-cel; planning for US commercial launch in 2026 Company funded into early 2026 with > $300 million including existing balance sheet, projected payments from partners, and other non-dilutive capital sources Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 4, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the Company's plans for its emerging sarcoma franchise including projections for peak US sales of up to $400 million. The Company will present plans for the franchise at the JP Morgan Healthcare Conference on January 11th from 8:15 to 8:55 a.m.
12/06 07:00 EST - newsfilecorp.com
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacy Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. Afami-cel is eligible for a Priority Review, which would shorten the FDA's review of the application to 8 months versus a standard review timeline of 12 months.
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacy Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. Afami-cel is eligible for a Priority Review, which would shorten the FDA's review of the application to 8 months versus a standard review timeline of 12 months.